DelveInsight’s “Chemotherapy-Induced Nausea and Vomiting Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Chemotherapy-Induced Nausea and Vomiting, historical and forecasted epidemiology as well as the Chemotherapy-Induced Nausea and Vomiting market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Unlock key insights into the Chemotherapy-Induced Nausea and Vomiting Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Chemotherapy-Induced Nausea and Vomiting Market Size

• Key Takeaways from the Chemotherapy-Induced Nausea and Vomiting Market Report
• In April 2025, Arbeitsgemeinschaft medikamentoese Tumortherapie conducted a phase III trial is to investigate the efficacy and safety of dronabinol (orally administered tetrahydrocannabinol (THC)) as adjuvant therapy to first-line standard chemotherapy in patients with metastatic pancreatic cancer for improvement of chemotherapy- and tumor-related symptoms applicated by individual titration up to the maximum tolerated dose.
• In March 2025, Xiamen LP Pharmaceutical Co., Ltd announced a phase 2 study to compare efficacy, safety and PK of palonosetron, a long-acting 5-HT3 receptor antagonist, by buccal film compared to iv injection for moderately emetogenic chemotherapy-induced nausea or vomiting (CINV) in cancer patients. Subjects are randomized into three treatment groups, two with the experimental study drug palonosetron in buccal film at one of two different doses or the control treatment using Palonosetron hydrochloride iv injection. Palonosetron PK will be assessed in a subgroup of each treatment group.
• The increase in Chemotherapy-Induced Nausea and Vomiting Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Chemotherapy-Induced Nausea and Vomiting Market is anticipated to witness growth at a considerable CAGR.
• The leading Chemotherapy-Induced Nausea and Vomiting Companies such as GlaxoSmithKline, Xiamen LP Pharmaceutical Co., Ltd, Merck Sharp & Dohme LLC, Shin Nippon Biomedical Laboratories Ltd., Solvay Pharmaceuticals, Solasia Pharma K.K., Helsinn Healthcare SA, Tesaro Inc., Heron Therapeutics and others.
• Promising Chemotherapy-Induced Nausea and Vomiting Pipeline Therapies such as GW679769, Dexamethasone, Ondansetron Hydrochloride, Casopitant, Fosaprepitant Dimeglumine, Intranasal granisetron and others.

Stay ahead in the competitive landscape of the Chemotherapy-Induced Nausea and Vomiting Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Chemotherapy-Induced Nausea and Vomiting Treatment Market Size

Chemotherapy-Induced Nausea and Vomiting Epidemiology Segmentation in the 7MM

The epidemiology section of Chemotherapy-Induced Nausea and Vomiting offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving Chemotherapy-Induced Nausea and Vomiting epidemiology trends @ Chemotherapy-Induced Nausea and Vomiting Prevalence

Chemotherapy-Induced Nausea and Vomiting Drugs Market

The Chemotherapy-Induced Nausea and Vomiting Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Chemotherapy-Induced Nausea and Vomiting signaling in Chemotherapy-Induced Nausea and Vomiting are likely to uncover new therapeutic targets and further expand treatment options for patients.

Chemotherapy-Induced Nausea and Vomiting Treatment Market Landscape

The Chemotherapy-Induced Nausea and Vomiting treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Chemotherapy-Induced Nausea and Vomiting has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To learn more about Chemotherapy-Induced Nausea and Vomiting treatment guidelines, visit @ Chemotherapy-Induced Nausea and Vomiting Treatment Market Landscape

Chemotherapy-Induced Nausea and Vomiting Companies

GlaxoSmithKline, Xiamen LP Pharmaceutical Co., Ltd, Merck Sharp & Dohme LLC, Shin Nippon Biomedical Laboratories Ltd., Solvay Pharmaceuticals, Solasia Pharma K.K., Helsinn Healthcare SA, Tesaro Inc., Heron Therapeutics and others.

Chemotherapy-Induced Nausea and Vomiting Market Outlook

The report’s outlook on the Chemotherapy-Induced Nausea and Vomiting market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Chemotherapy-Induced Nausea and Vomiting therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Chemotherapy-Induced Nausea and Vomiting drug and late-stage pipeline therapy.

Chemotherapy-Induced Nausea and Vomiting Drug Uptake

The drug chapter of the Chemotherapy-Induced Nausea and Vomiting report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages and disadvantages of each drug, as well as the latest news and press releases related to Chemotherapy-Induced Nausea and Vomiting.

Explore the dynamics of the Chemotherapy-Induced Nausea and Vomiting Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Chemotherapy-Induced Nausea and Vomiting Ongoing Clinical Trials Analysis

Scope of the Chemotherapy-Induced Nausea and Vomiting Market Report

• Coverage- 7MM
• Study Period- 2019-2032
• Chemotherapy-Induced Nausea and Vomiting Companies- GlaxoSmithKline, Xiamen LP Pharmaceutical Co., Ltd, Merck Sharp & Dohme LLC, Shin Nippon Biomedical Laboratories Ltd., Solvay Pharmaceuticals, Solasia Pharma K.K., Helsinn Healthcare SA, Tesaro Inc., Heron Therapeutics and others
• Chemotherapy-Induced Nausea and Vomiting Pipeline Therapies- GW679769, Dexamethasone, Ondansetron Hydrochloride, Casopitant, Fosaprepitant Dimeglumine, Intranasal granisetron and others.
• Chemotherapy-Induced Nausea and Vomiting Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Chemotherapy-Induced Nausea and Vomiting Unmet Needs, KOL’s views, Analyst’s views, Chemotherapy-Induced Nausea and Vomiting Market Access and Reimbursement

Table of Content

1. Key Insights

2. Executive Summary of Chemotherapy-Induced Nausea and Vomiting

3. Competitive Intelligence Analysis for Chemotherapy-Induced Nausea and Vomiting

4. Chemotherapy-Induced Nausea and Vomiting: Market Overview at a Glance

5. Chemotherapy-Induced Nausea and Vomiting: Disease Background and Overview

6. Chemotherapy-Induced Nausea and Vomiting Patient Journey

7. Chemotherapy-Induced Nausea and Vomiting Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Chemotherapy-Induced Nausea and Vomiting Unmet Needs

10. Key Endpoints of Chemotherapy-Induced Nausea and Vomiting Treatment

11. Chemotherapy-Induced Nausea and Vomiting Marketed Products

12. Chemotherapy-Induced Nausea and Vomiting Emerging Therapies

13. Chemotherapy-Induced Nausea and Vomiting: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Chemotherapy-Induced Nausea and Vomiting Market Outlook

16. Access and Reimbursement Overview of Chemotherapy-Induced Nausea and Vomiting

17. Chemotherapy-Induced Nausea and Vomiting KOL Views

18. Chemotherapy-Induced Nausea and Vomiting Market Drivers

19. Chemotherapy-Induced Nausea and Vomiting Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chemotherapy-induced-nausea-and-vomiting-market